Role of CD80 in stimulating T lymphocyte activation.
OBJECTIVE
To observe biological characteristics of hepatocarcinoma cells before and after CD80 transfection and to compare the effect of CD80-transfected hepatocarcinoma cells on T lymphocyte activation.


METHODS
Retro virus vector carrying CD80 gene was transfected into HepG2 cells to establish CD80-transfected hepatocarcinoma cells (HepG2/hCD80). Flow cytometry (FCM) was performed to detect CD80 expression in the transfected cells. RT-PCR was used to evaluate CD80 expression at mRNA level. In the presence of anti-CD3 mAb, the proliferation of T lymphocyte was observed by MTT. Meanwhile, the expression of activated molecule marker CD25 was analyzed through FCM.


RESULTS
A stable cell line HepG2/hCD80 expressing the human CD80 was established. Growth curve showed that the molecule CD80 could obviously decrease the growth of tumor cells. HepG2/hCD80 was evidenced to have a potency to enhance T cell proliferation and upregulate CD25 expression.


CONCLUSIONS
CD80 transfection can lower malignant phenotype of hepatocarcinoma cells. CD80 transfection has a down-regulatory effect to activated T cells in vitro.
Li
De-Chun
DC
Department of General Surgery, the First Affiliated Hospital of Soochow University, 96 Shizi Road, Suzhou 215006, Jiangsu Province, China.
Zhu
Xing-Guo
XG
Zhang
Yong
Y
Fu
Jian-Xin
JX
D015703:Antigens, CD / Q000235:genetics / Q000276:immunology; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines; D006528:Carcinoma, Hepatocellular; D045744:Cell Line, Tumor; D006801:Humans; D008113:Liver Neoplasms; D008213:Lymphocyte Activation; D016133:Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology*; D014162:Transfection
D015703:Antigens, CD; D018122:B7-1 Antigen; D019496:Cancer Vaccines